A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Patients With Influenza at High Risk of Influenza Complications
Phase of Trial: Phase III
Latest Information Update: 03 Oct 2017
At a glance
- Drugs S 033188 (Primary) ; Oseltamivir
- Indications Influenza virus infections
- Focus Registrational; Therapeutic Use
- Acronyms CAPSTONE-2
- Sponsors Shionogi
- 23 Feb 2017 Status changed from not yet recruiting to recruiting.
- 27 Oct 2016 Status changed from planning to not yet recruiting.
- 11 Sep 2016 New trial record